Dec 31, 2023
NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies Relapsed/Refractory Myeloma
NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies RRMM Study Assessing Activity of Intravenous (IV)...
164
Dec 1, 2022
NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets
NCT05308654: Phase 1: A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants with Relapsed or...
769
Dec 1, 2022
NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma
NCT05259839: Phase 1: (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for Relapsed/Refractory Multiple Myeloma A Study to...
483
Dec 18, 2021
NCT04721002: Evaluate t(11;14) Status & BCL2 Expression in Adult Participants With MM (MEDICI)
NCT04721002: Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM) (MEDICI) NCT04721002:...
78
Dec 24, 2020
NCT04570631: Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM
NCT04570631: Phase 1: Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or...
114
Dec 7, 2019
NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM
NCT04184050: Phase 1/2: Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217...
214
Dec 5, 2019
NCT03933735: Phase 1: ABBV-383 (TNB-383B) in Subjects With Relapsed or Refractory Multiple Myeloma
ABBV-383 (formerly TNB-383B) TNB-383B, a Bispecific Antibody Targeting BCMA BCMA x CD3 T-cell engaging bispecifc antibody RRMM...
504
Dec 8, 2018
NCT03539744: Phase 3 - A Study of Venetoclax/Dex Compared With Pomalidomide/Dex - t(11;14) +ive RRMM
CANOVA TRIAL t(11;14)-positive Relapsed or Refractory Multiple Myeloma. A Study of Venetoclax and Dexamethasone Compared With...
325
Dec 6, 2018
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
Multiple Myeloma Research Consortium MyDRUG RRMM NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG) Multiple...
369
Dec 8, 2017
NCT03314181: Phase 2 - Venetoclax, Daratumumab and Dex (+/- Bortezomib) in RRMM Multiple Myeloma
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed...
82
Dec 23, 2016
NCT02755597: NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM
Bellini RRMM A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as...
193
Dec 16, 2016
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory...
97
Dec 8, 2016
NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)
ELOQUENT-3 trial NCT02654132: Phase 2: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without...
307
Dec 20, 2013
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory MM
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma The phase 1 primary...
123
Dec 18, 2010
NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)
ELOQUENT - 2 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple...
100